Castle Biosciences, Inc.
CSTLNASDAQHealthcare● Active
$20.12
$-0.89(-4.24%)
Market Cap$610238634
P/E Ratio—
52W High$44.28
52W Low$14.59
Castle Biosciences, Inc. (CSTL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSTL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.34B | $0.33B | $0.22B | $0.14B | $0.09B |
| Cost of Revenue | $0.07B | $0.06B | $0.04B | $0.03B | $0.02B |
| Gross Profit | $0.27B | $0.27B | $0.17B | $0.11B | $0.08B |
| Gross Margin %(computed) | 79.37% | 81.87% | 79.53% | 76.64% | 83.18% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.05B | $0.05B | $0.04B | $0.03B |
| G&A Expenses | $0.09B | $0.08B | $0.07B | $0.06B | $0.00B |
| Total Operating Expenses | $0.32B | $0.26B | $0.24B | $0.18B | $0.12B |
| Operating Income | ($0.04B) | $0.01B | ($0.07B) | ($0.07B) | ($0.04B) |
| Operating Margin %(computed) | -12.44% | 2.61% | -30.93% | -53.16% | -42.60% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.03B) | $0.02B | ($0.06B) | ($0.07B) | ($0.04B) |
| Income Tax Expense | ($0.01B) | $0.00B | $0.00B | ($0.00B) | ($0.01B) |
| Net Income | ($0.02B) | $0.02B | ($0.06B) | ($0.07B) | ($0.03B) |
| Net Margin %(computed) | -7.02% | 5.49% | -26.15% | -48.99% | -33.26% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.83 | $0.66 | $-2.14 | $-2.58 | $-1.24 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | $0.01B | $0.04B | ($0.05B) | ($0.06B) | ($0.04B) |
| EBITDA Margin %(computed) | 3.30% | 11.48% | -20.49% | -42.57% | -38.91% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Castle Biosciences, Inc. data
About Castle Biosciences, Inc. (CSTL) Income Statement
Castle Biosciences, Inc. (CSTL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CSTL reported revenue of $0.34B, gross profit of $0.27B (gross margin 79.37%), and net income of ($0.02B) — a net profit margin of -7.02%.
Frequently asked questions
CSTL · 4 questionsCastle Biosciences, Inc. (CSTL) reported revenue of $0.34B for 2025, up 3.7% year-over-year.
CSTL revenueCSTL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08